美國最新高危型人乳頭狀瘤病毒檢測用于宮頸癌初篩指南介紹
發(fā)布時間：2018-10-30 15:22
【摘要】：繼2011年ACS(American Cancer Society,ACS)、ASCCP(American Society of Colposcopy and Cervica I Pathology,ASCCP)、ASCP(American Society of Clinical Pathology,ASCP)對宮頸癌及癌前病變篩查指南公布后,隨著幾項大型臨床研究數(shù)據(jù)的發(fā)表,支持hr HPV檢測用于初篩的證據(jù)越來越多。特別是在美國本土的一項前瞻性研究"滿足高級別HPV診斷需求(Addressing the Need for Advanced HPV Diagnostics,ATHENA)"試驗,揭示hr HPV檢測用于初篩在單輪篩查中對于CIN2、CIN3的敏感性優(yōu)于單獨細胞學篩查,并明確提出對hr HPV陽性女性分流的策略。本文旨在對美國最新hr HPV檢測用于宮頸癌初篩指南的新建議及相關(guān)證據(jù)進行介紹,同時提出對過渡期指南臨床應(yīng)用時帶來的問題包括hr HPV取樣的質(zhì)量控制以及可能存在不同于HPV致癌的其他腫瘤發(fā)生途徑等臨床研究的必要性。
[Abstract]:Following the release of ACS (American Cancer Society,ACS), ASCCP (American Society of Colposcopy and Cervica I Pathology,ASCCP), ASCP (American Society of Clinical Pathology,ASCP guidelines for screening cervical cancer and precancerous lesions in 2011, with the publication of data from several large clinical studies, Evidence supporting hr HPV testing for primary screening is increasing. In particular, a prospective study in the United States, "meeting the High level HPV Diagnostic needs (Addressing the Need for Advanced HPV Diagnostics,ATHENA)" trial, revealed that hr HPV testing was more sensitive to CIN2,CIN3 than single cytological screening in a single round of screening. The strategy of shunt hr HPV positive women was put forward. The purpose of this paper is to introduce the new recommendations and relevant evidence of the latest hr HPV test for cervical cancer screening in the United States. At the same time, the problems arising from clinical application of transitional guidelines include the quality control of hr HPV sampling and the necessity of clinical research on the possible existence of other tumorigenesis pathways different from HPV carcinogenesis.
【作者單位】： 南京醫(yī)科大學第一臨床醫(yī)學院;南京醫(yī)科大學第一附屬醫(yī)院婦科;
【分類號】：R737.33
[Abstract]:Following the release of ACS (American Cancer Society,ACS), ASCCP (American Society of Colposcopy and Cervica I Pathology,ASCCP), ASCP (American Society of Clinical Pathology,ASCP guidelines for screening cervical cancer and precancerous lesions in 2011, with the publication of data from several large clinical studies, Evidence supporting hr HPV testing for primary screening is increasing. In particular, a prospective study in the United States, "meeting the High level HPV Diagnostic needs (Addressing the Need for Advanced HPV Diagnostics,ATHENA)" trial, revealed that hr HPV testing was more sensitive to CIN2,CIN3 than single cytological screening in a single round of screening. The strategy of shunt hr HPV positive women was put forward. The purpose of this paper is to introduce the new recommendations and relevant evidence of the latest hr HPV test for cervical cancer screening in the United States. At the same time, the problems arising from clinical application of transitional guidelines include the quality control of hr HPV sampling and the necessity of clinical research on the possible existence of other tumorigenesis pathways different from HPV carcinogenesis.
【作者單位】： 南京醫(yī)科大學第一臨床醫(yī)學院;南京醫(yī)科大學第一附屬醫(yī)院婦科;
【分類號】：R737.33
【共引文獻】
相關(guān)期刊論文 前10條
1 王慧峰;;宮頸癌認知及篩查的臨床意義[J];甘肅醫(yī)藥;2013年10期
2 陳銳;趙健;廖秦平;;復(fù)方沙棘籽油栓治療宮頸HPV感染的臨床觀察[J];中國婦產(chǎn)科臨床雜志;2013年06期
3 孫選;韓韜;林峰;孔守芳;李旭日;劉愛紅;;宮頸病變患者配偶人乳頭瘤病毒感染的相關(guān)性臨床分析[J];中國婦產(chǎn)科臨床雜志;2014年01期
4 許曉躍;于農(nóng);陳建魁;張偉;;北京豐臺區(qū)女性人乳頭瘤病毒感染及分型[J];中國感染控制雜志;2013年06期
5 王健;曹昭;易珍;;2324例門診患者人乳頭瘤病毒感染狀況及亞型分析[J];廣西醫(yī)學;2014年01期
6 尤志學;;HPV16、18高危亞型的風險分層管理作用——更加有效的宮頸癌篩查舉措[J];國際檢驗醫(yī)學雜志;2014年03期
7 黃成琳;張淑蘭;;人乳頭瘤病毒衣殼蛋白與宮頸病變[J];國際婦產(chǎn)科學雜志;2014年02期
8 莫小亮;羅殿中;黨裔武;王莉;;不同程度宮頸病變單一、多重高危型HPV感染狀態(tài)下E6/E7 mRNA的表達[J];重慶醫(yī)學;2014年18期
9 魏葆s，
本文編號：2300382
本文鏈接：http://sikaile.net/yixuelunwen/fuchankeerkelunwen/2300382.html
最近更新
教材專著
